Starting August 2024, the Agency will process requests via RIMS, expand consultations for China's med device industry, and launch an NPRA pilot project.
Starting August 2024, the Agency for Medicines and Medical Devices will begin processing certain requests through the RIMS system. From August 5, this includes documentary quality control requests for drugs, and from August 12, it will expand to include various clinical trial-related requests, such as importing drugs for trials and reporting on clinical trials.
Three Important Points:
To further support the development of China's medical device industry, Hebei, Shandong, and Hubei Medical Device Innovation Service Stations have been added as participating units for pre-registration technical consultations. These consultations will begin on August 12, 2024, offering high-quality guidance to local medical device manufacturers. Consultations will be held every Thursday, with specific times and locations provided by each service station.
Three Important Points:
Learn more about China Medical Device Registration & Approval.
The NPRA is expanding its reliance approach to include new/additional indication applications through a 12-month pilot project starting on August 1, 2024. The project involves revised categories and criteria, as detailed in Appendix I. While NPRA aims to test new processes, they are also managing a high volume of variation applications with the same resources, making applicant cooperation crucial.
Three Important Points:
Learn more about MDA Malaysia Medical Device Registration.
Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Explore our collection of articles, success stories, and regulatory updates, designed to help you take your product global.
The IVDR transition includes structured processes IVD manufacturers must follow to engage with Notified Bodies. Many IVD manufacturers are interacting with Notified Bodies for the first time and must understand what is required to ensure a successful partnership. In this article, Dr. Oliver Eikenberg clarifies what manufacturers must prepare and when to engage a Notified Body for IVDR CE Marking.
Class D IVD manufacturers face fast-approaching IVDR transition deadlines, though some are more familiar with the regulatory process. In this article, Dr. Oliver Eikenberg discusses the difference between "new" and "old" Class Ds, and regulatory logistics they need to consider during the transition process.
Your IVD's intended purpose determines its classification, clinical evidence requirements, and clinical applications under the IVDR. Device companies will need a more robust intended purpose to fulfill IVDR criteria. In this article, Dr. Oliver Eikenberg explains the role of the intended purpose in IVDR compliance.
